bazedoxifene has been researched along with Hangman Fracture in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hara, T; Hijikata, Y; Matsubara, Y; Watanabe, N | 1 |
| Arias, L; Bueno, JAH; Komm, BS; Williams, R; Yu, CR | 1 |
| Lu, H; Luo, Q; Peng, L | 1 |
| Anastasilakis, AD; Makras, P; Yavropoulou, MP | 1 |
| Chines, A; Kaufman, JM; Palacios, S; Silverman, S; Sutradhar, S | 1 |
| Gatti, D; Lello, S; Rossini, M; Sblendorio, I | 1 |
| Chines, AA; de Villiers, TJ; Hines, T; Levine, AB; Mirkin, S; Nardone, Fde C; Palacios, S; Williams, R | 1 |
| Bushmakin, AG; Ellis, AG; Jansen, JP; Luo, X; Mirkin, S; Reginster, JY; Sutradhar, S; Williams, R | 1 |
| Bobula, J; Lips, P; van Schoor, NM; Yu, H | 1 |
| Johansson, H; Kanis, JA; McCloskey, EV; Oden, A | 1 |
| Iba, K; Takada, J; Yamashita, T | 1 |
| Adachi, JD; Chines, AA; Constantine, GD; Felsenberg, D; Kendler, DL; Kung, AW; Mairon, N; Silverman, SL; Teglbjærg, CS | 1 |
| Hadji, P | 1 |
| Bruyère, O; Chines, A; Detilleux, J; Reginster, JY | 2 |
7 review(s) available for bazedoxifene and Hangman Fracture
| Article | Year |
|---|---|
Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
Topics: Antibodies, Monoclonal; Bias; Bone Density; Bone Density Conservation Agents; Denosumab; Female; Femur Neck; Fractures, Spontaneous; Hip; Humans; Indoles; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Parathyroid Hormone-Related Protein; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Spinal Fractures; Teriparatide; Thiophenes; Watchful Waiting | 2021 |
Efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: A systematic review and meta-analysis.
Topics: Bone Density; Bone Density Conservation Agents; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Spinal Fractures; Spine; Time Factors; Treatment Outcome | 2017 |
Bazedoxifene for the treatment of osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Female; Humans; Indoles; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures | 2019 |
Pharmacokinetic evaluation of bazedoxifene for the treatment of osteoporosis.
Topics: Aged; Drug Evaluation; Estrogens, Conjugated (USP); Female; Humans; Indoles; Menopause; Osteoporosis, Postmenopausal; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome | 2013 |
Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women.
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Indoles; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Regression Analysis; Spinal Fractures; Treatment Outcome | 2014 |
[Diagnostic imaging of treatment in osteoporosis: SERM].
Topics: Absorptiometry, Photon; Bone and Bones; Bone Density; Female; Hip Fractures; Humans; Indoles; Osteoporosis; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Tomography, X-Ray Computed | 2011 |
The evolution of selective estrogen receptor modulators in osteoporosis therapy.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Endometrial Neoplasms; Female; Fractures, Bone; Hot Flashes; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Tetrahydronaphthalenes | 2012 |
7 trial(s) available for bazedoxifene and Hangman Fracture
| Article | Year |
|---|---|
Efficacy and safety of bazedoxifene in postmenopausal Latino women with osteoporosis.
Topics: Bone Density; Bone Remodeling; Collagen Type I; Double-Blind Method; Female; Fractures, Bone; Humans; Indoles; Latin America; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Placebos; Postmenopause; Selective Estrogen Receptor Modulators; Spinal Fractures | 2017 |
An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®.
Topics: Aged; Aged, 80 and over; Algorithms; Bone Density; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indoles; Kaplan-Meier Estimate; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Risk Assessment; Spinal Fractures; Treatment Outcome | 2013 |
Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study.
Topics: Aged; Bone Density Conservation Agents; Carcinoma, Ovarian Epithelial; Double-Blind Method; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Female; Humans; Incidence; Indoles; Middle Aged; Neoplasms, Glandular and Epithelial; Osteoporosis, Postmenopausal; Ovarian Neoplasms; Postmenopause; Selective Estrogen Receptor Modulators; Spinal Fractures; Ultrasonography; Vaginitis | 2013 |
Cross-geographic region differences in quality of life in women with and without vertebral fracture.
Topics: Aged; Body Mass Index; Bone Density Conservation Agents; Epidemiologic Methods; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Psychometrics; Quality of Life; Raloxifene Hydrochloride; Spinal Fractures | 2009 |
Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
Topics: Aged; Algorithms; Bone Density Conservation Agents; Double-Blind Method; Female; Fractures, Bone; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Risk Factors; Spinal Fractures | 2009 |
Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Placebos; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome | 2012 |
Relationships between changes in bone mineral density or bone turnover markers and vertebral fracture incidence in patients treated with bazedoxifene.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Remodeling; Collagen Type I; Double-Blind Method; Female; Humans; Indoles; Logistic Models; Middle Aged; Peptides; Placebo Effect; Selective Estrogen Receptor Modulators; Spinal Fractures; Spine | 2012 |
1 other study(ies) available for bazedoxifene and Hangman Fracture
| Article | Year |
|---|---|
A Bayesian path analysis to estimate causal effects of bazedoxifene acetate on incidence of vertebral fractures, either directly or through non-linear changes in bone mass density.
Topics: Bayes Theorem; Biostatistics; Bone Density; Bone Density Conservation Agents; Female; Humans; Indoles; Models, Statistical; Nonlinear Dynamics; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Spinal Fractures; Treatment Outcome | 2016 |